2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12C.05 KRASG12c-Mutant NSCLC Under Targeted Therapy in China: Lessons from Eight Cases

Pdf Summary

The study by Minqian Dai and colleagues examines the clinical outcomes of eight cases of KRASG12C-mutant non-small cell lung cancer (NSCLC) treated with KRASG12C inhibitors (KRAS G12Ci) in China. The research focuses on understanding the efficacy and characteristics of targeted therapy for this mutation type.<br /><br />Key findings include:<br />- All patients involved were male, and the majority (7 out of 8) were smokers.<br />- The cancer had metastasized to various sites, including the bones (75%), contralateral lung lobe, brain (25%), pleura, and adrenal gland.<br />- The lung cancer type was adenocarcinoma in all cases.<br />- There were concurrent mutations found alongside KRASG12C, including MET in one case, and more commonly, TP53 mutations in five cases (62.5%).<br /><br />The results highlighted that:<br />- Progressive disease (PD) occurred in 57.1% of patients, while 42.9% had stable disease (SD). No partial responses (PR) were achieved.<br />- The median overall survival (OS) was 19 months, with a confidence interval of 2.77-35.23 months.<br />- The median progression-free survival (PFS) was eight months, with a confidence interval of 2.22-13.78 months.<br />- For first-line treatments, the median OS was only three months, and the PFS was one month.<br /><br />The study concludes that the efficacy of KRAS G12Ci is relatively lower compared to other oncogene-targeted therapies for NSCLC. It suggests that larger, more comprehensive studies are required to accurately assess the efficacy of KRAS G12Ci and to identify potential markers for better patient classification and stratification for therapy. These findings underscore the complexity of treating KRASG12C-mutant NSCLC and indicate a need for more targeted research into therapeutic responses and possible improvements in treatment strategies.

Asset Subtitle

Minqian Dai

Meta Tag

Speaker Minqian Dai

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

KRASG12C-mutant

non-small cell lung cancer

NSCLC

KRASG12C inhibitors

targeted therapy

adenocarcinoma

TP53 mutations

progressive disease

overall survival

progression-free survival